How to Choose a GLP-1 Provider: 20 Checks Before You Pay

What is a "GLP-1 provider," really?

For this guide, a "GLP-1 provider" is the clinician or care organization responsible for evaluating and prescribing. A telehealth platform may arrange the care without being the prescriber itself. And "GLP-1" is common shorthand: semaglutide products like Wegovy and Ozempic are GLP-1 receptor agonists, while tirzepatide products like Zepbound and Mounjaro activate two receptors (GIP and GLP-1). Same conversation, slightly different drugs.

Most people picture one company. In reality, an online GLP-1 offer can involve four distinct roles, and the risky ones stay fuzzy about the three that carry the real responsibility.

Why does this matter? Because marketing collapses all four into the word "we." When you can name and verify all four, the care chain is clear enough to keep comparing. When a provider dodges any of them, you've found your first answer.

Keep one rule in mind: "not disclosed" is not the same as "verified." A provider hiding the pharmacy isn't proof of fraud -- but it does mean you don't have enough to pay confidently.

How to choose a GLP-1 provider: what should you check first?

Check the care chain before the price tag. Identify the platform, the medical group, the prescriber, and the pharmacy -- then confirm the prescriber is authorized to treat you where you'll be, and that the medication's status (FDA-approved or compounded) is stated plainly. Price only means something once you know those basics are real, because a cheap program from a source you can't verify isn't a deal.

1. Is there a real medical decision?

A legitimate program only prescribes after a licensed clinician reviews your health history, current medications, and anything that would make the drug unsafe. A short form that ends in a guaranteed prescription -- with no individualized clinician review -- is a checkout, not an evaluation.

2. Can you verify the prescriber for where you'll be?

"Doctor-led" and a white-coat photo aren't verification. You want the prescriber's name and credential, and you want them licensed or otherwise authorized to treat patients in the state where you'll be physically located during the visit. We'll show you the free lookups below.

3. Is the medication's status crystal clear?

Before you pay, the provider should tell you whether you're getting an FDA-approved medication (the FDA reviewed and approved that finished drug) or a compounded one (prepared by a licensed pharmacist, licensed physician, or registered outsourcing facility under compounding law; the finished compounded drug is not FDA-approved). These are two different treatment paths with different rules, and blurring them is a warning sign we'll return to.

4. Can you identify the pharmacy?

If your medication ships to your door, you should be able to find out which pharmacy fills it and confirm it's licensed -- in time to check it before it's dispensed. A provider that won't identify the pharmacy is asking you to trust an anonymous source with a prescription drug.

Should you choose your doctor, a specialist, a local clinic, or telehealth?

Any of these can be a good choice -- the right one depends on your health, not on whichever site promises the fastest start. Yale Medicine notes that a primary care doctor, an obesity-medicine specialist, or a telehealth provider can all be reasonable starting points, and that what matters most is a clinician who can actually follow you over time. (Yale Medicine) Match the care model to how complex your situation is, whether you want to use insurance, and how much support you need.

Fast isn't the same as good. Here's how to think about it.

If you're leaning toward telehealth, that's a reasonable choice -- plenty of people start there. Just go in knowing the platform, the prescriber, and the pharmacy may not be the same company, and hold each one to the checks above.

The right GLP-1 provider isn't the same for everyone -- it depends on your state, your insurance and formulary (the list of drugs your plan covers), whether you want an FDA-approved or compounded medication, your preferred treatment format (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

How do you choose between an FDA-approved and a compounded GLP-1?

Decide which treatment path you're evaluating before you compare prices, because the rules and the risks are different. FDA-approved GLP-1s have been reviewed by the FDA for safety, effectiveness, and quality. Compounded GLP-1s have not -- and as of 2026, the FDA is actively restricting them and cracking down on ads that make them sound equivalent to the brand. That turns "compounded vs. FDA-approved" from a price question into a legitimacy question.

The broad compounding window has closed. Compounding is when a pharmacy or facility prepares a custom drug. For a couple of years, GLP-1 shortages allowed pharmacies to compound semaglutide and tirzepatide at scale. Those shortages were declared resolved -- tirzepatide on December 19, 2024, and semaglutide on February 21, 2025 -- and the related enforcement periods ended in 2025. Broad, "anyone can get it" compounding tied to a shortage is no longer permitted. Compounding can still happen only when the conditions of section 503A or 503B are met.

The FDA is now enforcing, hard. On February 6, 2026, the FDA announced it intends to restrict the ingredients used in mass-marketed compounded GLP-1s and to go after misleading direct-to-consumer marketing. Its statement is blunt: companies can't market a compounded product as a "generic" version of, or "the same as," an FDA-approved drug; can't say it uses the "same active ingredient"; and can't say it's "clinically proven." (FDA) The agency then announced 30 warning letters to telehealth companies on March 3, 2026 (FDA), and enforcement has continued since.

And a bigger rule is pending. On April 30, 2026, the FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. That proposal is not final; the FDA extended the public comment period through July 30, 2026. (Federal Register) If finalized, it would close the 503B outsourcing-facility pathway for these drugs; it would not erase every lawful form of compounding.

What FDA approval tells you

• The FDA reviewed that finished drug and its labeling.
• You can look it up and see its approved uses.
• It does not guarantee it's right for you personally or that insurance will cover it.

What compounded status tells you

• The finished compounded drug is not FDA-approved, and the FDA hasn't checked its quality, safety, or effectiveness before it's sold.
• A real prescription and a properly licensed pharmacy still matter.
• Marketing that calls it equivalent to the brand isn't just a stretch -- it may break FDA rules.

What "503B registered" means (and doesn't)

You'll see providers wave around "503B" like a seal of approval. A 503B outsourcing facility is one that elects to register with the FDA under section 503B and meets that section's conditions. Registration is not approval.

None of this means compounded medicine is always wrong -- it has real, legitimate uses for specific patients. It means that in 2026, if a provider is mass-marketing compounded semaglutide or tirzepatide to anyone with a form and calling it "the same" as the brand, you're looking at a provider on the wrong side of active FDA enforcement. If you specifically want an FDA-approved medication, keep those comparisons completely separate from compounded ones.

What should a GLP-1 provider's medical evaluation include?

A legitimate evaluation collects enough relevant history and context for a licensed clinician to make an individual decision -- it isn't a guaranteed-prescription checkout. There's no single required lab panel that proves a provider is legit; the clinician should decide what records, exam, or testing you need. What you're checking is whether a real clinical decision happens, not whether it matches a fixed script.

Watch for these signs of a real process:

• An individual decision, not a promise. "Guaranteed approval" can't coexist with an honest, individualized prescribing decision.
• Someone qualified reviews your information. A licensed clinician -- not just customer support -- makes the medical call.
• The format fits the situation. A legitimate evaluation may be by video, phone, or an online form, depending on you, the clinician, and state rules. The format matters less than whether a real decision is made and documented.
• Records and testing are handled sensibly. The provider should be able to explain how the clinician decides whether your records, an exam, or lab work are needed before or during care.
• A follow-up owner is named. You should know who's responsible after the first prescription.

If any part of this feels like a vending machine -- money in, prescription out, no clinician in the middle -- that's your cue to keep looking.

Does insurance change how you should choose a GLP-1 provider?

Yes -- your insurance situation should steer which provider you pick. If you want an FDA-approved drug and have coverage, prioritize a provider that checks your formulary, confirms whether the visit is in-network, and handles prior authorization (your insurer's permission step before it pays). If you're paying cash, focus on the treatment path and the full recurring cost, not the first-month teaser.

One rule protects you either way: never let a provider show you a compounded monthly price sitting next to an FDA-approved price with no label. They're different products under different rules. Compare like with like.

For the full picture on GLP-1 insurance coverage, see our GLP-1 insurance coverage guide -- Medicare, Medicaid, employer plans, and how to fight a denial.

How does the 20-point provider check work?

It's a 20-point check, grouped under five pillars, that you run on the provider you're considering -- before you pay. You mark each item verified, not verified, or unknown; six category-level hard stops override everything else; and you get one of three results: Ready to compare, Needs answers, or Do not pay yet. It doesn't rank the provider or grade the medicine. It tells you whether you have enough solid information to move forward.

This is a reader-side evidence tool -- not a medical opinion and not accreditation. Items that feed one of the six hard stops are marked.

How do you verify the clinician can actually treat you?

Get the medical group's name and the prescriber's name and credential, then check them with the right board for where you'll be during care. A "board-certified doctors" banner isn't proof. Because telehealth rules depend on your location, the clinician must be authorized to treat you in the state where you're physically located -- and how they're authorized can vary. (HHS)

Ask the two questions that cut through the marketing:

• "Which medical group provides the clinical evaluation and is responsible for my prescription?"
• "Will I get the prescribing clinician's full name and credential before a prescription is issued?"

If the answer is vague or "our doctors handle that," that's your signal.

Check the right source for the credential:

• MD or DO → your state medical or osteopathic board. For physicians, FSMB's DocInfo (docinfo.org) is an added licensure and disciplinary source.
• NP → your state nursing board.
• PA → your state medical or PA board.
• NPI Registry (npiregistry.cms.hhs.gov): helps confirm an identity or practice record, but an NPI is just a 10-digit administrative identifier -- it does not verify current licensure, credentials, or the right to practice. Use the state board for that.
• For board certification specifically, verify through the named certifying board -- for many physicians, that's ABMS's Certification Matters (certificationmatters.org).

Check your location, not the platform's headquarters. "Available nationwide" doesn't prove a specific clinician can treat someone in your specific state. Save what you find -- the name, credential, state, license status, the date you checked, and any open question.

How do you verify the pharmacy and medication source?

For mailed medication, find out which pharmacy fills it, then check that pharmacy through your state board and the FDA's tools. The National Association of Boards of Pharmacy (NABP) has flagged more than 40,000 non-compliant pharmacy websites and estimates that nearly 95% of sites selling prescription drugs online operate out of step with the law. (NABP)

Use the FDA's BeSafeRx guidance as a floor. (FDA BeSafeRx) NABP's Safe Site Search lets you paste a website address to see if it's recognized -- treat that as one extra signal, not the whole answer.

How should an online GLP-1 provider protect your health information?

Before you enter health information, figure out which company receives it, whether the clinical entity is covered by HIPAA, and whether your data is used for advertising. A privacy-policy link alone doesn't prove that every company in the platform's care chain is HIPAA-covered. HIPAA protects information handled by covered health providers and their business associates, but some vendors sit outside HIPAA, and separate state consumer-health-data laws may also apply. This is one of the biggest blind spots in online care.

Because "the provider" can be several companies, ask where your data lands:

• Which entity gets it? The clinical entity and the platform entity may be different companies with different rules.
• Is there a clear privacy notice that names who receives your information and why?
• Is your health data shared for advertising or analytics? Some platforms use tracking tools that send data to third parties.
• Can you access and export your records, and how do you file a privacy complaint?

You don't need to become a privacy lawyer. You just need to know who's holding your health information before you hand it over -- and a provider that can answer plainly is showing you something important about how it operates.

What follow-up care should a good GLP-1 provider offer?

Pick a provider that spells out, before you start, who handles dose changes, refills, side-effect questions, and when to seek in-person care. The responsible team, the way to reach them, and the plan for problems should never be a mystery. Yale Medicine's experts put it plainly: you want a prescriber who works with you over time, not one who writes a prescription and disappears. (Yale Medicine)

GLP-1 treatment isn't a one-and-done prescription. Many FDA-approved incretin medications use a labeled dose-escalation schedule, and common side effects differ by product. Ask these before you pay, and notice whether the answers name a licensed clinician or just "support":

• "Which clinician reviews my dose changes, and what do they use to decide?"
• "How do I reach a licensed clinical team if I have a medication concern -- portal, phone, or message?"
• "Is a refill automatic, form-based, or reviewed by a clinician?"
• "How will you tell me if I need local, in-person, or urgent care?"
• "Can I get my records, and can you coordinate with my regular doctor?"

Match each question to who should own it: billing questions go to support, but anything about the medication itself should reach a clinician or pharmacist. A chatbot may route your question -- it shouldn't replace access to a real clinician for a medication decision.

How do you calculate the real cost of a GLP-1 provider?

Ignore the first-month teaser and compare the full 90-day and 12-month cost -- membership, medication, dose changes, labs, shipping, and the cost to cancel. The number that protects you is the total you'll actually pay over a year, plus what it costs to leave. An advertised "$99" may be introductory, limited to a starter dose, or exclude required fees.

Break every provider into four prices:

1. The intro price -- the first-month hook.
2. The ongoing platform fee -- the recurring membership.
3. The medication price -- often the biggest number, and it can change by dose.
4. Required extras -- labs, visits, shipping.

Two rules keep this honest. First, don't fill an unknown with an optimistic guess. If a provider says "medication from $X" but won't say what changes it, mark your annual medication cost unresolved. Second, compare like with like -- don't stack a cash-pay compounded price against an insured brand-name copay, or an intro price against a maintenance price.

Here's why "starting at" pricing can fool you. The FDA-approved oral GLP-1 Foundayo launched through the manufacturer's direct program at a self-pay price starting at $149/month for the lowest dose -- but that climbs to $199, $299, or $349 a month as the dose goes up (verified July 2026). (Lilly) That's medication pricing from the manufacturer, not an all-in provider-program cost -- and it's exactly the kind of dose-based jump to build into your 12-month math.

Which cancellation, renewal, and refill terms matter most?

Before your first payment, find out when charges renew, how you cancel, what happens to a pending medication order, and how refill or pharmacy changes are handled. The time to understand the exit is before you're in -- not after the next charge hits. Billing and cancellation risk is only understandable when renewal, refund, pending-order, and exit terms are visible before you pay.

Get clear answers to these:

• Renewal: When does it renew -- monthly or prepaid? Does canceling stop only platform charges, or medication orders too? Is notice required before a cutoff?
• Refunds: What happens if you're not prescribed? Is the consult or membership fee refundable? What if the medication is unavailable?
• Pending orders: Can a pharmacy order already in process be stopped? Is it refundable? Could canceling the platform leave an active shipment?
• Refills and supply: How early can a refill be reviewed? What if the pharmacy changes?

Save a screenshot of the terms with the date. If a provider makes canceling hard to find or understand, that tells you how they'll treat you as a customer.

What should you collect before switching GLP-1 providers?

You can switch -- but the new clinician has to do their own evaluation, and they may not continue the same medication, dose, or pharmacy. Before you move, gather your current prescription and last dose, your prescribing clinician's info, your dispensing pharmacy, any relevant records or test results, your refill timing, and the status of any pending shipment or charge. Walking in with that packet makes the handoff smooth instead of a gap in your supply.

How do you compare two GLP-1 providers side by side?

Run the six hard stops on each provider first, then compare only the ones still standing -- on treatment-path fit, access, follow-up, transparency, and full 90-day and 12-month cost. A provider with an unresolved hard stop drops out before you ever get to price. That one habit saves you from talking yourself into a cheaper option that can't clear the basics.

A quick way to do it in a few minutes:

1. Identify the care chain for each -- platform, medical group, prescriber, pharmacy.
2. Verify the clinician and pharmacy using the free lookups above.
3. Check the treatment-path language -- FDA-approved or compounded, with no blurring.
4. Check the follow-up -- clinical messaging, dose and refill review, escalation.
5. Do the cost math -- 90-day, 12-month, and exit cost.
6. Turn every unknown into a question and send it before you decide.

Then line your finalists up in a simple worksheet -- provider, care model, medical group, prescriber verified, pharmacy verified, treatment path, follow-up owner, intro price, ongoing price, 90-day total, 12-month total, cancellation path, open questions, and the date you checked. When it's on one page, the right choice usually gets obvious.

Which red flags mean you should walk away?

Walk away from no-prescription sales, unverifiable clinicians, hidden pharmacies, misleading FDA-approved-vs-compounded claims, guaranteed results, undisclosed recurring charges, and no clinical support. A polished website, a big review count, or a trust badge does not cancel out missing evidence. When a hard stop can't be resolved, choosing someone else is the smart move.

A note on urgency: countdown timers and "only 3 spots left" are pressure tactics, not reasons. The only real urgency is this -- prices, availability, and policies change, so verify before you pay, then act with confidence.

When is telehealth not the best choice?

Telehealth may be the wrong first stop if you need urgent care, an in-person exam, tightly coordinated management of complex conditions, or continuity a platform can't provide. In those cases, start with a primary care doctor, an obesity-medicine specialist, an endocrinologist, or local care. Convenience is real, but it's not worth it if your situation needs hands-on management.

Be honest with yourself if any of these fit:

• You need urgent or emergency care. This guide and our tools are not emergency resources. Call 911 for an emergency; for a non-emergency urgent concern, contact appropriate local urgent or in-person care.
• Your care needs close coordination -- several clinicians managing related conditions, an existing specialist who needs to be in the loop, or findings that need an in-person exam.
• The platform can't serve your location. Don't use a different address or hide where you are to get around state rules -- that can disrupt your care and place the visit outside the clinician's authorized practice.
• You value continuity over speed. A local or existing clinician who'll follow you for a year may beat a platform that starts you next-day.

If that's you, telehealth isn't a failure -- it's just not your best first move. Come back to it when the fit is right.

What did The RX Index actually verify for this guide?

We checked the regulatory and verification claims here against the FDA, HHS, NABP, and state-board resources. The 20-check framework and its results are editorial decision tools -- not government accreditation, medical advice, or a guarantee of any provider's safety, your eligibility, or insurance coverage.

Who made this: The RX Index Editorial Team, under our published editorial oversight. How: we developed the framework from the sources and decision criteria described here, drawing on search-intent and voice-of-customer research, primary-source verification, and human editorial review. Why: so you never pay before you can verify the people, the pharmacy, the treatment path, the support, and the true cost behind a GLP-1 offer.

Frequently asked questions

Choosing a provider comes down to verifiable clinical responsibility, a clearly disclosed treatment path, real follow-up, access where you are, and complete cost. The questions below cover the edge cases that commonly stop someone from making a confident decision before they pay.